Orion Corp. has entered into a license agreement with Janssen Pharmaceuticals for the development and commercialization of Orion’s investigational alpha-2c adrenoceptor antagonists for the symptoms of Alzheimer’s disease, including clinical phase compound ORM-12741.   Orion will receive an upfront payment of $31 million and is eligible to receive payments upon completion of certain development and commercialization milestones, as well as royalties on future sales. Orion will use the ...